SandboxAlonso
Stage IV
Is pleural or pericardial effusion present (suggestive of M1a) or are findings suggestive of systemic metastasis (M1b) present? | |||||||||||||||||||||||||||||||||||||||||||||
M1a | M1b: solitary site systemic metastasis | ||||||||||||||||||||||||||||||||||||||||||||
Perform the following tests:
| Perform the following tests:
| ||||||||||||||||||||||||||||||||||||||||||||
Is the liquid extracted positive for malignant cells? | Are findings suggestive of adrenal metastasis or brain metastasis? | ||||||||||||||||||||||||||||||||||||||||||||
Yes | No | Adrenal | Brain | ||||||||||||||||||||||||||||||||||||||||||
Local therapy
PLUS | Perform a needle aspiration biopsy for metastasis confirmation | Surgical resection + adjuvant radiation therapy Radiation therapy alone:
PLUS | |||||||||||||||||||||||||||||||||||||||||||
What is the TN stage of the lung tumor? | |||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||
| Administer therapy for metastatic disease in case of not curable lung lesions (click here for the treatment of local and systemic metastasis and neoplastic recurrence) | ||||||||||||||||||||||||||||||||||||||||||||
Multiple lung cancers
Is there suspicion of multiple lung cancers? | |||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||
Administer treatment according to the TNM stage of the tumor | |||||||||||||||||||||||||||||||||
Is the disease is confined to the chest or is there systemic proliferation? | |||||||||||||||||||||||||||||||||
Disease confined to the chest | Systemic proliferation | ||||||||||||||||||||||||||||||||
Assess the mediastinal lymph nodes in order to determine the N stage of the tumor | Click here for the treatment of systemic metastasis | ||||||||||||||||||||||||||||||||
What is the N stage of the tumor? | |||||||||||||||||||||||||||||||||
N0-1 | N2-3 | ||||||||||||||||||||||||||||||||
Is the patient symptomatic? | Click here for the treatment of systemic metastasis | ||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||
Is the lesion a solitary nodule or are there multiple nodules? | |||||||||||||||||||||||||||||||||
Solitary nodule | Multiple nodules | ||||||||||||||||||||||||||||||||
What is the risk of turning into a symptomatic disease? | |||||||||||||||||||||||||||||||||
High | Low | ||||||||||||||||||||||||||||||||
Is definitive local therapy possible? | Observation | ||||||||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||||||||
Consider palliative chemotherapy with or without local radiation therapy | Administer one of the following tratments:
| ||||||||||||||||||||||||||||||||
Click here for the treatment of systemic metastasis | Click here for the follow-up recommendations and treatment of recurrence and metastasis | ||||||||||||||||||||||||||||||||
Follow-up
Controls of history + physical exam and chest CT with or without contrast every 6-12 months (first 2 years), then annual controls | |||||||||||||||||||||||||
Is there evidence of local or regional recurrence OR systemic metastasis? | |||||||||||||||||||||||||
Local or regional recurrence | Systemic metastasis | ||||||||||||||||||||||||
Local or regional recurrence
What is the site of the recurrence? | |||||||||||||||||||||||||||||||||||||||||||
Bronchial obstruction | Mediastinal lymph node | Superior vena cava obstruction | Severe hemoptisis | Resectable tumor | |||||||||||||||||||||||||||||||||||||||
Surgical correction of the obstruction: laser therapy, stent or any other surgical procedure OR Radiation therapy (external-beam or brachytherapy) OR Photodynamic therapy | Has the patient received radiation therapy? | Chemotherapy + radiation therapy OR External-beam radiation therapy OR Superior vena cava stent collocation | Surgery OR Radiation therapy (external-beam or brachytherapy) OR Laser therapy, photodynamic therapy or tumor embolization | Tumor resection (preferred option) OR Radiation therapy (stereotactic ablative radiotherapy or external-beam radiation therapy) | |||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||
Administer systemic therapy | Administer chemotherapy + radiation therapy | ||||||||||||||||||||||||||||||||||||||||||
Are findings suggestive of disseminated disease present? | |||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||
Click here for the treatment of metastatic disease | Observation OR systemic therapy | ||||||||||||||||||||||||||||||||||||||||||
Systemic metastasis
What are the characteristics of the metastasis? | |||||||||||||||||||||||||||||||||||||||||||
Diffuse brain metastasis | Bone metastasis | Localized symptoms | Solitary metastasis | Multiple metastasis | |||||||||||||||||||||||||||||||||||||||
External-beam radiation therapy (palliative) | External-beam radiation therapy (palliative) + limb stabilization (prevention of pathological fractures) Denosumab or biophosphonate therapy should be considered | External-beam radiation therapy (palliative) | Click here for the treatment of stage IV M1b (solitary site metastasis) | Click here for the treatment of metastatic disease | |||||||||||||||||||||||||||||||||||||||
Click here for the treatment of metastatic disease | |||||||||||||||||||||||||||||||||||||||||||
Metastatic disease
What the specific subtype according to the specific histological characteristics of the tumor? | |||||||||||||||||||||||||||||||||||||||
| Squamous cell carcinoma | ||||||||||||||||||||||||||||||||||||||
Perform specific EGFR and ALK mutation testing: What is the specific mutation? | Is the patient a smoker or former smoker? | ||||||||||||||||||||||||||||||||||||||
Sensitizing EGFR mutation | ALK mutation | Negative EGFR and ALK | Click here for the squamous cell carcinoma specific treatment | ||||||||||||||||||||||||||||||||||||
Click here for the sensitizing EGFR mutation specific treatment | Click here for the specific therapy for the ALK mutation specific treatment | Click here for the treatment of negative sensitizing EGFR and ALK mutation metastatic disease | |||||||||||||||||||||||||||||||||||||
Third line therapy
The algorithm below shows the third line therapy for metastatic disease according to the 2014 NCCN Non-Small Cell Lung Cancer guidelines.
What is the performance status of the patient? | |||||||||||||||||||||||||||||||
PS 0-2 | PS 3-4 | ||||||||||||||||||||||||||||||
If not previously used, administer any of the following:
| Administer erlotinib or provide suportive care | ||||||||||||||||||||||||||||||
What is the performance status of the patients after the treatment? | |||||||||||||||||||||||||||||||
PS 0-2 (stable tumor) | PS 3-4 (tumor progression) | ||||||||||||||||||||||||||||||
Provide supportive care or try experimental treatments | Provide supportive care | ||||||||||||||||||||||||||||||
Chemotherapy followed by radiotherapy
The list bellow show the options for chemotherapy followed by radiation therapy based on the 2014 NCCN Non-Small Cell Lung Cancer guidelines.[1]
- Cisplatin 100 mg/m2 on days 1 and 29 + vinblastin 5 mg/m2 per week on days 1, 8, 15, 22 and 29, then followed by radiation therapy.
- Paclitaxel 200 mg/m2 administered for 3 hours in the first day + carboplatin AUC 6 administered in 1 hour and then every 21 days to a total of 2 cycles followed by thoracic radiation therapy.
Chemotherapy plus radiotherapy, followed by chemotherapy
The list bellow show the options for concomitant chemotherapy plus radiation therapy followed by chemotherapy based on the 2014 NCCN Non-Small Cell Lung Cancer guidelines.[1]
- Cisplatin 50 mg/m2 on days 1, 8, 29 and 36 + etoposide 50 mg/m2 through day 1 to 5 and then 29 to 33 + thoracic radiation therapy, then followed by cisplatin 50 mg/m2 + etoposide 50 mg/m2 to a total of 2 cycles.
- Paclitaxel 45 to 50 mg/m2 once a week + carboplatin AUC 2 + thoracic radiation therapy, then followed by Paclitaxel 200 mg/m2 + carboplatin AUC 6 to a total of 2 cycles.